Søgning på udtrykket 'pseudomonas' giver 40 resultater
Nyt fra tidsskrifterne [+20]
Aktuelle smitsomme sygdomme [+20]
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se
flere resultater her?
Journal of Infectious Diseases
14.09.2023
AbstractWe describe 2 cases of extensively drug-resistant Pseudomonas aeruginosa infection caused by a strain of public health concern, as it was recently associated with a nationwide outbreak of contaminated artificial tears. Both cases were detected through database review of genomes in the Enhanced Detection System for Hospital-Associated Transmission (EDS-HAT), a routine genome sequencing–based surveillance program. We generated a high-quality reference genome for the outbreak strain from an isolate f
Clinical Microbiology and Infection
2.09.2023
Cefiderocol is a last resort option for carbapenem-resistant (CR) Gram-negative bacteria, especially metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa and CR Acinetobacter baumannii. Monitoring global levels of cefiderocol non-susceptibility (CFDC-NS) is important.
PLoS One Infectious Diseases
16.08.2023
tic material, may be a way to stop the spread of antibiotic-resistant genes. The effect of 5,10,15,20-(pyridinium-3-yl)porphyrin tetrachloride (TMPyP3) without light, and after activation with violet-blue light (VBL) (394 nm; 20 mW/cm2), on MDR strains of Pseudomonas aeruginosa, Klebsiella pneumoniae and K. pneumoniae OXA-48 in tap water and municipal wastewater was investigated. High toxicity (~2 μM) of TMPyP3 was shown in the dark on both strains of K. pneumoniae in tap water, while on P. aeruginosa toxi
PLoS One Infectious Diseases
12.08.2023
by Matteo Zucchini, Antonietta Maoloni, Enrico Maria Lodolini, Ilario Ferrocino, Lucia Aquilanti, Davide Neri . Olive knot is a widely spread disease among olive (Olea europaea L.) trees. Pseudomonas savastanoi pv. savastanoi is recognized as the primary causative agent of the disease however, recent evidence indicated that consortia of bacteria (pathobiome), may favor its development. Several factors are involved in the host-plant relationship and affect the intensity of the symptoms. Among these the pres
PLoS One Infectious Diseases
4.08.2023
by Sepideh Fereshteh, Fatemeh Haririzadeh Jouriani, Narjes Noori Goodarzi, Mahdi Torkamaneh, Behnoush Khasheii, Farzad Badmasti . Background Multidrug-resistant Pseudomonas aeruginosa has become a major cause of severe infections. Due to the lack of approved vaccines, this study has presented putative vaccine candidates against it. Methods P. aeruginosa 24Pae112 as a reference strain was retrieved from GenBank database. The surface-exposed, antigenic, non-allergenic, and non-homologous human proteins were
Proceedings of the National Academy of Sciences
21.07.2023
Proceedings of the National Academy of Sciences, Volume 120, Issue 30, July 2023.
Infection
18.07.2023
. Abstract. . Background. P. aeruginosa bacteremia is a common and severe infection carrying high mortality in older adults. We aimed to evaluate outcomes of P. aeruginosa bacteremia among old adults (≥ 80 years). . . . Methods. We included the 464/2394 (19%) older adults from a retrospective multinational (9 countries, 25 centers) coho
PLoS One Infectious Diseases
14.07.2023
ction of 82 bacterial strains isolated from marine water and sediment samples collected from the Southwestern Gulf of Mexico. Eight of the marine isolates inhibited the growth of different pathogenic bacteria, seven of which were identified as presumptive Pseudomonas aeruginosa. Interestingly, genome sequencing and phylogenetic analysis revealed that the remaining marine isolate showing antibacterial activity is a novel Pseudomonas species that we denominated Pseudomonas sp. GOM7, which was not pathogenic i
PLoS One Infectious Diseases
12.07.2023
by Meghan J. Hirsch, Emily M. Hughes, Molly M. Easter, Seth E. Bollenbecker, Patrick H. Howze IV, Susan E. Birket, Jarrod W. Barnes, Megan R. Kiedrowski, Stefanie Krick . Pseudomonas aeruginosa (PA) is known to chronically infect airways of people with cystic fibrosis (CF) by early adulthood. PA infections can lead to increased airway inflammation and lung tissue damage, ultimately contributing to decreased lung function and quality of life. Existing models of PA infection in vitro commonly utilize 1–6-h
Antimicrobial Agents And Chemotherapy
11.07.2023
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Clinical Microbiology and Infection
8.07.2023
Hospital-acquired bacterial pneumonia (HABP) is the most common healthcare-associated infection in the United States and a leading cause of morbidity, mortality and healthcare expense among hospitalized patients. Pseudomonas aeruginosa (PsA) is the second most common causative pathogen in HABP and a major therapeutic challenge: compared to other pathogens, patients with PsA-HABP experience higher rates of antimicrobial resistance, treatment failure, pneumonia recurrence, and mortality.1 Improving treatment
Antimicrobial Agents And Chemotherapy
6.07.2023
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Infection and Immunity
5.07.2023
Infection and Immunity, Ahead of Print.
Antimicrobial Agents And Chemotherapy
4.07.2023
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Antimicrobial Agents And Chemotherapy
23.06.2023
Antimicrobial Agents and Chemotherapy, Ahead of Print.
PLoS One Infectious Diseases
15.06.2023
by Oliver J. Hills, Zuzanna Poskrobko, Andrew J. Scott, James Smith, Helen F. Chappell . Intravenous gallium therapy is a non-antibiotic approach to limit Pseudomonas aeruginosa biofilm proliferation, by outcompeting iron for siderophore binding. Gallium therapy represents a viable therapeutic strategy for cystic fibrosis (CF) patients harbouring mucoid P. aeruginosa biofilm lung infections. Siderophore deficient P. aeruginosa isolates still demonstrate a hindered biofilm proliferation when exposed to gall
Antimicrobial Agents And Chemotherapy
15.06.2023
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Antimicrobial Agents And Chemotherapy
14.06.2023
Antimicrobial Agents and Chemotherapy, Ahead of Print.
American Journal of Tropical Medicine and Hygiene
7.06.2023
. . Journal Name: The American Journal of Tropical Medicine and Hygiene Volume: 108 Issue: 6 Pages: 1220-1226. .
Antimicrobial Agents And Chemotherapy
5.06.2023
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se
flere resultater her?
Morbidity and Mortality Weekly Report (MMWR)
4.08.2023
This report describes an investigation of two cases of carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa among ICU patients who stayed in the same hospital room.
ProMED
6.04.2023
P. aeruginosa -- United StatesFederal inspectors found dozens of issues at an eye drops manufacturer now linked to a fatal outbreak of drug-resistant bacteria, inspection records released by the Food and Drug Administration show, ranging from dirty equipment and clothing to missing safeguards and procedures.The FDA's findings were detailed in citations issued to Indian manufacturer Global Pharma Healthcare Pvt Ltd after an inspection from 20 Feb through 2 Mar 2023. This appears to have been the company's 1s
ProMED
18.03.2023
P. aeruginosa -- United States'As of 14 Mar 2023, CDC, in partnership with state and local health departments, identified 68 patients in 16 states (CA, CO, CT, FL, IL, NC, NJ, NM, NY, NV, PA, SD, TX, UT, WA, WI) with VIM-GES-CRPA, a rare strain of extensively drug-resistant _P. aeruginosa_. Thirty-seven patients were linked to 4 healthcare facility clusters. One person has died and there have been 8 reports of vision loss and 4 reports of enucleation (surgical removal of eyeball). Dates of specimen collecti
ProMED
8.02.2023
nosa -- United StatesThe Food and Drug Administration (FDA) has warned against using 'Artificial Tears' eye drops produced by a Tamil Nadu-based firm after an outbreak of drug-resistant infections was linked to the drug in the USA. This is the 3rd such controversy involving an Indian pharma company.Another controversy has hit India's pharmaceutical industry as the United States warned that an eye drop manufactured by a Tamil Nadu-based firm has caused an outbreak of the drug-resistant bacterium _Pseudomonas
ProMED
4.02.2023
P. aeruginosa -- United StatesPatients should stop using EzriCare Artificial Tears pending additional information and guidance from CDC and FDA. If patients were advised to use EzriCare Artificial Tears by their healthcare provider, they should follow up with their healthcare provider for recommendations about alternative treatment options. Patients who have used EzriCare preservative-free artificial tears and who have signs or symptoms of an eye infection should seek medical care immediately. At this time,
ProMED
2.02.2023
P. aeruginosa -- United StatesOne person has died and at least 3 others are left with permanent vision loss because of a bacterial infection possibly linked to a brand of over-the-counter eyedrops, according to the Centers for Disease Control and Prevention (CDC). A majority of those affected reported using preservative-free EzriCare Artificial Tears before becoming ill, CDC reported in a statement dated 20 Jan 2023. While the infections have not been definitively traced to the eyedrops, CDC recommended tha
ProMED
8.05.2022
Hospital-Related Infection -- Norway
Eurosurveillance latest updates
5.05.2022
In November 2021, a clonal outbreak of Pseudomonas aeruginosa of novel sequence type ST3875 was detected in three patients who died of bloodstream infections in one hospital. By 25 April 2022, the outbreak included 339 cases from 38 hospitals across Norway. Initial hospital reports indicate Pseudomonas infection as the main contributing cause in seven deaths. In March 2022, the outbreak strain was identified in non-sterile pre-moistened disposable washcloths, used to clean patients, from three lots from the
ProMED
19.04.2022
P. aeruginosa -- Bangladesh
Morbidity and Mortality Weekly Report (MMWR)
23.05.2019
Verona integron-encoded metallo-β-lactamase-producing carbapenem-resistant Pseudomonas aeruginosa and other carbapenemase-producing organisms represent an emerging U.S. public health threat.
Morbidity and Mortality Weekly Report (MMWR)
31.05.2018
Eurosurveillance latest updates
5.05.2022
In November 2021, a clonal outbreak of Pseudomonas aeruginosa of novel sequence type ST3875 was detected in three patients who died of bloodstream infections in one hospital. By 25 April 2022, the outbreak included 339 cases from 38 hospitals across Norway. Initial hospital reports indicate Pseudomonas infection as the main contributing cause in seven deaths. In March 2022, the outbreak strain was identified in non-sterile pre-moistened disposable washcloths, used to clean patients, from three lots from the
Morbidity and Mortality Weekly Report (MMWR)
4.08.2023
This report describes an investigation of two cases of carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa among ICU patients who stayed in the same hospital room.
ECDC COVID-19 updates
27.05.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21-27 May 2023 May 2023 and includes updates on COVID-19, influenza, Marburg virus disease, poliomyelitis, extensively drug-resistant Pseudomonas aeruginosa, and suspected fungal meningitis.
ECDC Communicable Disease Threats Report
26.05.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21-27 May 2023 May 2023 and includes updates on COVID-19, influenza, Marburg virus disease, poliomyelitis, extensively drug-resistant Pseudomonas aeruginosa, and suspected fungal meningitis.
Eurosurveillance latest updates
19.05.2023
. Background. Antimicrobial resistance (AMR) is of public health concern worldwide. . . Aim. We aimed to summarise the German AMR situation for clinicians and microbiologists. . . Methods. We conducted a systematic review and meta-analysis of 60 published studies and data from the German Antibiotic-Resistance-Surveillance (ARS). Primary outcomes were AMR proportions in bacterial isolates from infected patients in Germany (2016–2021) and the case fatality rates (2010–2021). Random and fixed (common)
ECDC Communicable Disease Threats Report
11.04.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-25 March 2023 and includes updates on Marburg virus disease, iatrogenic botulism, COVID-19, Influenza, Group A streptococcal infection, cholera, poliomyelitis, measles, and extensively drug-resistant Pseudomonas aeruginosa.
ECDC COVID-19 updates
25.03.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-25 March 2023 and includes updates on Marburg virus disease, iatrogenic botulism, COVID-19, Influenza, Group A streptococcal infection, cholera, poliomyelitis, measles, and extensively drug-resistant Pseudomonas aeruginosa.
Eurosurveillance latest updates
8.09.2022
and caused by Pseudomonas aeruginosa (6.2% vs 2.0%), fungi (2.9% vs 1.4%) and multidrug-resistant (MDR) pathogens (2.2% vs 1.8%), which were also predictors of death within 2 days in the model. . . Conclusions. Overrepresentation of polymicrobial, fungal, P. aeruginosa and MDR aetiology among BSI leading to early death is challenging concerning the initial antimicrobial treatment. Our findings highlight the need for active prevention and prompt recognition of BSI and appropriate antimicrobial treatment.
Eurosurveillance latest updates
5.05.2022
In November 2021, a clonal outbreak of Pseudomonas aeruginosa of novel sequence type ST3875 was detected in three patients who died of bloodstream infections in one hospital. By 25 April 2022, the outbreak included 339 cases from 38 hospitals across Norway. Initial hospital reports indicate Pseudomonas infection as the main contributing cause in seven deaths. In March 2022, the outbreak strain was identified in non-sterile pre-moistened disposable washcloths, used to clean patients, from three lots from the